NCT00000505

Phase 3Interventional

Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

View on ClinicalTrials.gov ↗

Timeline

Start date: Apr 1, 1983
Primary completion: —
Completion date: Dec 1, 1990
First posted: —
Last posted: —
Enrollment: —
Arms / groups: — / —
Source: AACT · pre-existing

Sponsors

National Heart, Lung, and Blood Institute (NHLBI)Lead sponsor
Tufts UniversityOfficial
University of WashingtonOfficial
Northwestern UniversityOfficial
Yale UniversityOfficial
New York Medical CollegeOfficial
University of VermontOfficial
Columbia UniversityOfficial
Rhode Island HospitalOfficial
Yeshiva UniversityOfficial
University of MassachusettsOfficial
Mayo ClinicOfficial
Maryland Medical Research InstituteOfficial
Cornell UniversityOfficial
New York UniversityOfficial
Harvard UniversityOfficial
George Washington UniversityOfficial
Baylor UniversityOfficial
Icahn School of Medicine at Mount SinaiOfficial
University of MinnesotaOfficial
Washington University in St. LouisOfficial
University of ChicagoOfficial
St. Louis UniversityOfficial
United States ArmyOfficial
University of Alabama, BirminghamOfficial
The University of Texas, DallasOfficial

Drugs studied

alteplase

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.